Array's pain drug clears PhII 'high hurdle' but QT signs raise some flags
22:50 EDT 1 Aug 2012 | SCRIP
Array BioPharma's CEO was on the defensive on 1 August as the company's stock fell 15.2% on the company's news released after the market closed a day earlier that ARRY-797 provided statistically significant pain relief in a Phase II clinical trial;...
Original Article: Array's pain drug clears PhII 'high hurdle' but QT signs raise some flags
More From BioPortfolio on "Array's pain drug clears PhII 'high hurdle' but QT signs raise some flags"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
